GTx, Inc. Announces the Appointments of Andrew M. Clarkson and J. Kenneth Glass to its Board of Directors

GTx, Inc. Announces the Appointments of Andrew M. Clarkson and J. Kenneth Glass
to its Board of Directors 


MEMPHIS, Tenn., March 2  /PRNewswire-FirstCall/ -- Mitchell Steiner, M.D.,
F.A.C.S., Vice Chairman and CEO of GTx, Inc.  today announced the appointments
of Andrew M. Clarkson and J. Kenneth Glass to the Company's Board of Directors.

Mr. Clarkson will serve as Chairman of the Board's Audit Committee and will be a
member of the Board's Nominating and Corporate Governance Committee. Subsequent
to working in senior financial positions at General Foods Corporation and as
Vice President/Treasurer of F.W. Woolworth, Mr. Clarkson became Chief Financial
Officer and a Board Director of Malone & Hyde, Inc., where he played a pivotal
role in taking Malone & Hyde private.  This first-ever cash tender offer
leveraged buyout resulted in the formation of AutoZone, Inc., an auto parts
chain that subsequently became a NYSE-listed company in 1991 and today comprises
more than 3,000 stores with sales over $5billion.  Mr. Clarkson remained on the
Board of AutoZone, Inc. through November 2001.

Mr. Clarkson graduated from Oxford University, attended McGill University and
earned an MBA from Harvard Business School.  He currently serves on the Boards
of Amphenol Corporation, Royal Furniture and TruckPro, Inc., and is actively
involved with not-for-profit organizations through board positions at the
Memphis Arts Council, The Lifeblood Foundation, The New Canaan Elder Care
Council and the Jeniam Foundation.

Mr. Glass is currently Chairman, President and Chief Executive Officer of First
Tennessee National Corporation and First Tennessee Bank, N.A. (NYSE:FTN), one of
the nation's 50 largest bank holding companies with total assets of $24.5
billion.  Mr. Glass will serve on both the Board's Audit Committee and
Compensation Committee. Mr. Glass brings extensive financial expertise to the
Board, having worked in a range of capacities at First Tennessee National
Corporation and First Tennessee Bank, N.A. for the past 30 years.  Prior to
joining First Tennessee, Mr. Glass served as an audit manager and CPA for Arthur
Andersen and Company.

Mr. Glass received his B.A. in Accounting from Harding University and graduated
from Harvard Business School's Advanced Management Program.  He currently serves
on the Board of Directors for FedEx Corporation.

About GTx, Inc.

GTx is a biopharmaceutical company dedicated to the discovery, development and
commercialization of therapeutics primarily related to the treatment of serious
men's health conditions.  GTx's drug discovery and development programs are
focused on small molecules that selectively modulate the effects of estrogens
and androgens.  GTx currently has two product candidates that are in human
clinical trials.  The company is developing Acapodene, its most advanced product
candidate, through clinical trials for two separate indications:  (1) a Phase
IIb clinical trial for the reduction in the incidence of prostate cancer in men
with precancerous prostate lesions and (2) a pivotal Phase III clinical trial
for the treatment of serious side effects of advanced prostate cancer therapy.
GTx is developing its second product

candidate, Andarine, for the treatment of muscle wasting weight loss, or
cachexia, that occurs from various types of cancer.

   CONTACT:   Carney Duntsch
              Manager, Corporate Communications
              GTx, Inc.
              901-523-9700 ext. 170


DATASOURCE: GTx, Inc.



CONTACT:  Carney Duntsch, Manager, Corporate Communications of GTx, Inc.,

[phone], ext. 170

Copyright